Filing Details

Accession Number:
0001179110-21-001510
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-10 16:24:29
Reporting Period:
2021-02-08
Accepted Time:
2021-02-10 16:24:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070081 Ptc Therapeutics Inc. PTCT Pharmaceutical Preparations (2834) 043416587
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1707685 Marie Christine Utter C/O Ptc Therapeutics, Inc.
100 Corporate Court
South Plainfield NJ 07080
Svp, Finance & Cao No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-08 2,657 $33.02 19,166 No 4 M Direct
Common Stock Disposition 2021-02-08 2,657 $66.00 16,509 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-02-08 2,657 $33.02 2,657 $33.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
21,250 2029-01-21 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (Right To Buy) $490.80 2021-04-27 74 74 Direct
Common Stock Stock Option (Right To Buy) $218.40 2022-01-10 21 21 Direct
Common Stock Stock Option (Right To Buy) $40.45 2024-09-23 4,688 4,688 Direct
Common Stock Stock Option (Right To Buy) $51.00 2025-01-02 17,800 17,800 Direct
Common Stock Stock Option (Right to Buy) $18.01 2028-01-02 10,000 10,000 Direct
Common Stock Stock Option (Right To Buy) $33.02 2029-01-21 10,100 10,100 Direct
Common Stock Stock Option (Right To Buy) $51.16 2030-01-28 23,800 23,800 Direct
Common Stock Stock Option (Right to Buy) $66.49 2031-01-05 50,750 50,750 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2021-04-27 74 74 Direct
2022-01-10 21 21 Direct
2024-09-23 4,688 4,688 Direct
2025-01-02 17,800 17,800 Direct
2028-01-02 10,000 10,000 Direct
2029-01-21 10,100 10,100 Direct
2030-01-28 23,800 23,800 Direct
2031-01-05 50,750 50,750 Direct
Footnotes
  1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 14, 2020.
  2. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
  3. Currently exercisable.
  4. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
  5. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
  6. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
  7. Represents an option award of 33,250 options and an option award of 17,500 options. These option awards were each granted on January 6, 2021, and each vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.